NRSN — Neurosense Therapeutics Share Price
0.000.00%
Last trade - 00:00- $13.20m
- $12.52m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -602.4% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 13th, 2017
- Public Since
- December 9th, 2021
- No. of Shareholders
- 7
- No. of Employees
- 16
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 18,037,006
- Address
- 11 Hamenofim St., Building B, HERZLIYA, 4672562
- Web
- https://www.neurosense-tx.com/
- Phone
- +972 99531142
- Auditors
- Somekh Chaikin
Upcoming Events for NRSN
Q2 2024 Neurosense Therapeutics Ltd Earnings Release
Similar to NRSN
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Neurosense Therapeutics share price?
As of Today at 22:16 UTC, shares in Neurosense Therapeutics are trading at $0.90. This share price information is delayed by 15 minutes.
How has the Neurosense Therapeutics share price performed this year?
Shares in Neurosense Therapeutics last closed at $0.90 and the price had moved by -43.88% over the past 365 days. In terms of relative price strength the Neurosense Therapeutics share price has underperformed the S&P500 Index by -55.34% over the past year.
What are the analyst and broker recommendations for Neurosense Therapeutics?
The overall consensus recommendation for Neurosense Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Neurosense Therapeutics dividend yield?
Neurosense Therapeutics does not currently pay a dividend.
Does Neurosense Therapeutics pay a dividend?
Neurosense Therapeutics does not currently pay a dividend.
When does Neurosense Therapeutics next pay dividends?
Neurosense Therapeutics does not currently pay a dividend.
How do I buy Neurosense Therapeutics shares?
To buy shares in Neurosense Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Neurosense Therapeutics?
As of the previous close price of $0.90, shares in Neurosense Therapeutics had a market capitalisation of $16.20m.
Where are Neurosense Therapeutics shares listed?
Here are the trading details for Neurosense Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NRSN
What kind of share is Neurosense Therapeutics?
Based on an overall assessment of its quality, value and momentum Neurosense Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Neurosense Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Neurosense Therapeutics is $5.25. That is 484.63% above the last closing price of $0.90.
Analysts covering Neurosense Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.73 for the next financial year.
What is the trend in the Neurosense Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neurosense Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +1.15%.
As of the last closing price of $0.90, shares in Neurosense Therapeutics were trading -16.22% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Neurosense Therapeutics PE Ratio?
The Neurosense Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Neurosense Therapeutics?
We do not have data on Neurosense Therapeutics' directors